Contrary to what drugmakers are purporting, price hikes on drugs are not the result of rebates, according to a study commissioned by the Pharmaceutical Care Management Association.

Based on an analysis by Visante of price growth and estimated rebate levels for the top 200 brand drugs by 2016 U.S. sales, the PCMA study finds no correlation between the increasing prices that drugmakers set on individual drugs and the rebates they negotiate with pharmacy benefit managers on those products.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

  • Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
  • Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
  • Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Katie Kuehner-Hebert

Katie Kuehner-Hebert is a freelance writer based in Running Springs, Calif. She has more than three decades of journalism experience, with particular expertise in employee benefits and other human resource topics.